How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

487 results for

Superficial Thrombophlebitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. The Vaginal Health Trial

/No). pH [ Time Frame: Week 12 ] Objective measures of genitourinary atrophy: pH (<5 or >5) at week 12 Vaginal Maturation Index [ Time Frame: Week 12 ] Objective Measures of Genitourinary Atrophy: Vaginal Maturation Index (VMI) described by % parabasal, intermediate, and superficial cells (≤ 5% or >5% superficial cells) at week 12 Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor (...) , attempting pregnancy or breast feeding Current acute vaginal infection (as indicated by wet mount at V1) Pelvic or vaginal surgery in prior 60 days Antibiotic use in the past 30 days Women under age 55 with endometrial ablation Women under age 55 with hysterectomy and at least one ovary Current cancer treatment (exception basal or squamous skin cell cancers) Current or past thromboembolic disease (pulmonary embolus or deep vein thrombosis, not including thrombophlebitis), myocardial infarction or stroke

2015 Clinical Trials

162. The Prevention of Pain Associated With Rocuronium Injection

18- 70 years of ASA (American Society of Anesthesiologists) physical status I- II who were to undergo various elective operations. None of the patients was premedicated before the operation. The patients were monitored with three derivation electrocardiogram, non- invasive arterial pressure, and pulse oximeter. A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes (...) With Acetaminophen and Lidocaine Study Start Date : May 2014 Actual Primary Completion Date : September 2014 Actual Study Completion Date : October 2014 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Placebo Comparator: Placebo (Group I) For pretreatment the patients were administered IV 5ml normal saline. A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated

2015 Clinical Trials

163. A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

myocardial infarction (MI) within the past 6 months and/or at the time of screening are treated with anticoagulants and/or antiplatelet agents (excluding aspirin) for a previous myocardial infarction. Have a history of: abnormal bleeding, clotting events or disorders (excluding a history of clotted hemodialysis access or superficial thrombophlebitis in the absence of medically confirmed coagulopathy), any coagulopathy (documented or clinically suspected) For example, participants should be excluded

2015 Clinical Trials

164. Laser Ablation Versus Mechanochemical Ablation Trial

by (Responsible Party): Daniel Carradice, University of Hull Study Details Study Description Go to Brief Summary: A randomised clinical trial comparing endovenous laser ablation and mechanochemical ablation (ClariVein®) in the management of superficial venous insufficiency. Condition or disease Intervention/treatment Phase Varicose Veins Device: Endovenous Laser Ablation Device: Mechanochemical Ablation Drug: Lidocaine with 1:200,000 epinephrine solution Drug: Sodium Bicarbonate Drug: Sodium Tetradecyl (...) better results. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 140 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Randomised Clinical Trial Comparing Endovenous Laser Ablation and Mechanochemical Ablation (ClariVein®) in the Management of Superficial Venous Insufficiency Study Start Date : June 2015 Estimated Primary Completion

2015 Clinical Trials

165. Clinical Study of Stent Versus Direct Atherectomy Versus Angioplasty to Treat Lower Limb In-stent Restenosis

, Beijing. Recruitment status was: Recruiting First Posted : July 13, 2016 Last Update Posted : July 13, 2016 Sponsor: Xuanwu Hospital, Beijing Information provided by (Responsible Party): Xuanwu Hospital, Beijing Study Details Study Description Go to Brief Summary: This is a randomized study comparing Stent Versus Direct Atherectomy Versus Angioplasty to Treat Lower Limb In-stent Restenosis (superficial femoral or popliteal artery). Condition or disease Intervention/treatment Phase Atherosclerosis (...) In-stent Arterial Restenosis Device: plaque excision system Device: stent Device: Balloon Not Applicable Detailed Description: This is a randomized study comparing Stent Versus Direct Atherectomy Versus Angioplasty to Treat Lower Limb In-stent Restenosis (superficial femoral or popliteal artery). Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 120 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking

2015 Clinical Trials

166. Lake Washington Vascular VenaSealâ„¢ Post-Market Evaluation (WAVES)

, or active acute superficial thrombophlebitis, or thrombophlebitis migrans; Previous treatment such as laser or radiofrequency ablation of venous disease in targeted vein segment; Known hypercoagulable disorder; Pregnant or breast feeding at enrollment; Known sensitivity to cyanoacrylate adhesives; Venous treatment in the contralateral limb within the last 30 days, or who require contralateral treatment within three months; Planned to undergo additional ipsilateral treatments on the same leg within 3 (...) ): Lake Washington Vascular Study Details Study Description Go to Brief Summary: The VenaSeal Closure system offers an outpatient treatment option for the permanent closure of lower extremity superficial truncal veins, such as the great saphenous vein (GSV), through endovascular embolization with coaptation. VenaSeal is intended for use in adults with clinically symptomatic venous reflux as diagnosed by duplex ultrasound (DUS). Condition or disease Intervention/treatment Phase Venous Reflux Device: SP

2015 Clinical Trials

167. Transdermal Patch CVD 1000: The Effect of Heat on Nicotine Release From Nicotine Patches in Adult Smokers

reactions not evaluable 17. Subject who currently has any of the following conditions: Thrombophlebitis, thromboembolic disorders A past history of deep vein thrombophlebitis or thromboembolic disorders Cerebrovascular or coronary artery disease (current or past history) Valvular heart disease with complications Severe hypertension Diabetes with vascular involvement Headaches with focal neurological symptoms Major surgery with prolonged immobilization 18. Medical history of a serious chronic condition (...) (e.g. allergic conditions such as anaphylaxis, asthma or generalized drug reaction). 19. Medical history of significant dermatologic diseases or conditions, such as atopy, psoriasis, vitiligo or conditions known to alter skin appearance or physiologic response (e.g. diabetes, porphyria). 20. History of significant dermatologic cancers (e.g. melanoma, squamous cell carcinoma), except basal cell carcinomas that were superficial and did not involve the investigative site. 21. Within 10 hours prior

2015 Clinical Trials

168. Lenalidomide and Obinutuzumab for Previously Untreated CLL

(if applicable), including development of erythema nodosum or a desquamating rash while taking thalidomide or similar drugs. Deep vein thrombosis or superficial thrombophlebitis of any cause on current anticoagulation therapy at the time of screening. Patients who are currently receiving another investigational agent are excluded. Current infection requiring parenteral antibiotics. Known seropositive for or active viral infection with human immunodeficiency virus (HIV); or known active infection

2015 Clinical Trials

169. Evaluation of the Immune Restoration Potential Of Lenalidomide

testing as required in the Revlimid REMS® program. Exclusion Criteria: Progressive CLL requiring therapy based on 2008 international working group guidelines (iwCLL 2008, Hallek et al, Blood 2008). Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. Known hypersensitivity to thalidomide or lenalidomide. Prior lenalidomide-associated deep vein thrombosis Deep vein thrombosis or superficial (...) thrombophlebitis of any cause on current anticoagulation therapy at the time of screening. Patients who are currently receiving another investigational agent are excluded. Patients who have had chemotherapy (e.g., purine analogues, alkylating agents), radiation therapy, tyrosine kinase inhibitor therapy, or participation in any investigational drug treatment within 4 weeks of initiation of lenalidomide or at any time during the study. Patients who have had prior (within 8 weeks of initiation of lenalidomide

2015 Clinical Trials

170. Efficacy and Safety of Esarin Gel in Chronic Venous Insufficiency and Varicose Veins

Information provided by (Responsible Party): Ten Sun Pharma Company Limited Study Details Study Description Go to Brief Summary: Evaluation efficacy and safety of Esarin Gel in subjects with chronic venous insufficiency or varicose veins combine superficial vein thrombophlebitis. Condition or disease Intervention/treatment Phase Chronic Venous Insufficiency Varicose Vein Superficial Vein Thrombophlebitis Drug: Esarin Gel Phase 4 Detailed Description: Open-label,non-controlled study design with three (...) visits (pre-treatment/baseline, treatment day 14 and day 28). Administered Esarin Gel twice daily for 28 days in subjects with chronic venous insufficiency rated between CEAP 0 and 3 or varicose veins combine superficial vein thrombophlebitis, in comparison to the pre-treatment. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 53 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose

2015 Clinical Trials

171. Diagnosis of Mondor's Disease in the Emergency Department with Bedside Ultrasound Full Text available with Trip Pro

Diagnosis of Mondor's Disease in the Emergency Department with Bedside Ultrasound Mondor's disease is a rare condition characterized by a superficial thrombophlebitis that can occur in the thoracoabdominal and genital areas. Findings with ultrasound in penile Mondor's disease are readily measurable: a noncompressible penile vein without flow and absence of tears of the corpus cavernosum or tunica albuginea, hematoma, or evidence of fracture of the penis. We present a case of Mondor's disease

2015 Case Reports in Emergency Medicine

172. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study. Full Text available with Trip Pro

anaphylactoid reaction and 1 had grade 2 superficial thrombophlebitis. Other adverse events were mild to moderate and included headache, fatigue, infusion site reactions, and urinary tract infection.PDA-001 infusions were safe and well tolerated in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis patients. No paradoxical worsening of lesion counts was noted with either dose.Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.

2015 Multiple sclerosis and related disorders Controlled trial quality: predicted high

173. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer Full Text available with Trip Pro

[ ]. The bacterial pathogens that cause most bloodstream infections in the setting of neutropenia are listed in . Fungi are rarely identified as the cause of first fever early in the course of neutropenia; rather, they are encountered after the first week of prolonged neutropenia and empirical antibiotic therapy. Yeasts, primarily Candida species, may cause superficial infections of mucosal surfaces (eg, thrush); chemotherapy-induced mucositis, in turn, may disrupt this barrier [ ], allowing Candida to enter

2010 Infectious Diseases Society of America

174. Penile Mondor’s disease Full Text available with Trip Pro

Penile Mondor’s disease Mondor's disease is a rare, self-limiting, benign process with acute presentation characterized by subcutaneous bands in several parts of the body. Penile Mondor's disease (PMD) is thrombophlebitis of the superficial dorsal vein of the penis. It is usually considered as thrombophlebitis or phlebitis of subcutaneous vessels. Some findings suggest that it might be of lymphatic origin. The chest, abdominal wall, penis, upper arm, and other parts of the body may also (...) be involved by the disease. Although its physiopathology is not exactly known, transection of the vessel during surgery or any type of trauma such as external compression may trigger its possible development. This disease almost always limits itself. It may be associated with psychological distress and sexual incompatibility. The patients usually feel the superficial vein of the penis like a hard rope and present with complaint of pain around this hardness. Diagnosis is usually easy with physical

2014 Basic and Clinical Andrology

175. Prophylaxis of Ileostomy Closure Site Hernia by Placing Mesh

independently. Respiratory complications [ Time Frame: 30 days after surgery ] Pneumonia, Atelectasis, Pulmonary embolism, Respiratory distress syndrome ... This is a Clinical measure always supported by image . All the morbidity problems are reported independently. Vascular Complications [ Time Frame: 30 days after surgery ] Deep venous thrombosis, phlebitis, thrombophlebitis, ... This is a Clinical measure supported by more specific test if necessary . All the morbidity problems are reported independently (...) disorientation. Local infection [ Time Frame: 30 days after surgery ] Superficial, deep, body-cavity This is a Clinical measure supported by image if necessary All the morbidity problems are reported independently Local complications [ Time Frame: 30 days after surgery ] Hematoma, seroma, evisceration This is a Clinical measure All the morbidity problems are reported independently Hospital stay [ Time Frame: Days ] Hospital stay since surgery is done Eligibility Criteria Go to Information from the National

2014 Clinical Trials

176. Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

Capsule Drug: Estradiol Experimental: Estradiol 25mcg Vaginal Softgel Capsule Estradiol 25mcg Vaginal Softgel Capsule Drug: Estradiol Placebo Comparator: Placebo Vaginal Softgel Capsule Placebo Vaginal Softgel Capsule Drug: Placebo Outcome Measures Go to Primary Outcome Measures : Co-Primary Efficacy Endpoint - Vaginal Superficial Cells [ Time Frame: Baseline and 12 Weeks ] • Change from Baseline to Week 12 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo (...) from Baseline to Week 12 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12 Secondary Outcome Measures : Secondary Efficacy Endpoints - Vaginal Superficial Cells [ Time Frame: Baseline and Week 2 ] • Change from Baseline to Week 2 in the percentage of vaginal

2014 Clinical Trials

177. Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

to be resistant to dalbavancin or vancomycin (vancomycin MIC (minimum inhibitory concentration) >8 μg/mL). Evidence of meningitis, necrotizing fasciitis, gas gangrene, gangrene, septic arthritis, osteomyelitis; endovascular infection, such as clinical and/or echocardiographic evidence of endocarditis or septic thrombophlebitis. Infections caused exclusively by Gram-negative bacteria (without Gram-positive bacteria present) and infections caused by fungi, whether alone or in combination with a bacterial (...) as assessed by a vascular surgeon. Participants with ABSSSI such as superficial/simple cellulitis/erysipelas, impetiginous lesion, furuncle, or simple abscess that only requires surgical drainage for cure. Concomitant condition requiring any antibiotic therapy that would interfere with the assessment of study drug for the condition under study. Anticipated need of antibiotic therapy for longer than 14 days. Participants who are placed in a hyperbaric chamber as adjunctive therapy for the ABSSSI. More than

2014 Clinical Trials

178. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. (Abstract)

emboli were detected and no clinically important neurologic or visual adverse events were reported. The most common adverse events in patients treated with polidocanol endovenous microfoam were retained coagulum, leg pain and superficial thrombophlebitis; most were related to treatment and resolved without sequelae.Polidocanol endovenous microfoam provided clinically meaningful benefit in treating symptoms and appearance in patients with varicose veins. Polidocanol endovenous microfoam

2014 Phlebology / Venous Forum of the Royal Society of Medicine Controlled trial quality: uncertain

179. Achieving predictability in augmentation mastopexy. (Abstract)

documented.At a mean follow-up of 38 months, major complications included 16 revisions and one readmission for superficial thrombophlebitis. The majority of revisions were for scar revision or implant size change. Minor complications included two hematomas, one seroma, three T-point skin sloughs, and two minor infections. There were no instances of major flap loss or nipple loss.The technique described provides a safe and conservative surgical approach for one-stage augmentation mastopexy resulting

2014 Plastic and reconstructive surgery

180. Benign Vulvar Lesions (Follow-up)

a pseudomembranous coating. Vulvar ulcers, ranging in diameter from a few millimeters to 3 cm, often appear as multiple crops of well-defined and very tender ulcers with fibrinous bases and considerable undermining. Fistulae, with partial or complete destruction of the labia, may develop. Other manifestations of the disease include fever, malaise, acneiform lesions or cutaneous nodules on the skin, arthritis, synovitis, and thrombophlebitis. Associated erythema nodosum and erythema multiforme have been reported (...) ). Lymphangioma This condition is usually detected early in infancy on the labia minora or majora as an asymptomatic, raised, compressible, doughy mass, sometimes showing multiple clustered, superficial, thin-walled, translucent, and persistent pseudovesicles filled with clear fluid that may progressively grow over time. [ ] Angiokeratoma Angiokeratomas manifest as 1-3 mm, dark, red-to-purple, and sometimes hyperkeratotic papules. Patients are usually asymptomatic. Benign vulvar lesions. Angiokeratomas

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>